- Home
- DBD vs GLPG Comparison
DBD vs GLPG Comparison
Compare DBD & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- GLPG
- Stock Information
- Founded
- DBD 1859
- GLPG 1999
- Country
- DBD United States
- GLPG Belgium
- Employees
- DBD N/A
- GLPG N/A
- Industry
- DBD EDP Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- GLPG Health Care
- Exchange
- DBD Nasdaq
- GLPG Nasdaq
- Market Cap
- DBD 1.9B
- GLPG 2.0B
- IPO Year
- DBD N/A
- GLPG 2005
- Fundamental
- Price
- DBD $60.05
- GLPG $32.56
- Analyst Decision
- DBD Strong Buy
- GLPG Sell
- Analyst Count
- DBD 2
- GLPG 4
- Target Price
- DBD $75.00
- GLPG $25.33
- AVG Volume (30 Days)
- DBD 198.1K
- GLPG 422.1K
- Earning Date
- DBD 08-06-2025
- GLPG 07-23-2025
- Dividend Yield
- DBD N/A
- GLPG N/A
- EPS Growth
- DBD N/A
- GLPG N/A
- EPS
- DBD N/A
- GLPG N/A
- Revenue
- DBD $3,672,300,000.00
- GLPG $323,674,692.00
- Revenue This Year
- DBD $2.02
- GLPG N/A
- Revenue Next Year
- DBD $1.96
- GLPG N/A
- P/E Ratio
- DBD N/A
- GLPG N/A
- Revenue Growth
- DBD N/A
- GLPG 5.43
- 52 Week Low
- DBD $34.38
- GLPG $22.36
- 52 Week High
- DBD $61.01
- GLPG $33.86
- Technical
- Relative Strength Index (RSI)
- DBD 63.94
- GLPG 58.14
- Support Level
- DBD $53.93
- GLPG $31.91
- Resistance Level
- DBD $60.57
- GLPG $33.86
- Average True Range (ATR)
- DBD 1.55
- GLPG 0.92
- MACD
- DBD 0.02
- GLPG -0.11
- Stochastic Oscillator
- DBD 86.39
- GLPG 74.41
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.